Medical Cannabis in Australia: Legal Status, Access Pathways and Patient Guide (2026)

Last updated: January 2026

Medical cannabis is legal in Australia under a tightly regulated federal framework, but the rules governing who can access it, how it is prescribed, and what products are permitted are often misunderstood. This guide explains the current legal landscape, the Therapeutic Goods Administration (TGA) approval pathways, what patients can realistically expect, and how the medical framework differs from recreational cannabis, which remains illegal across all Australian states and territories.

This article is educational in nature. It is not medical advice. If you believe medical cannabis may be appropriate for your situation, speak with a registered Australian healthcare practitioner.

Is Medical Cannabis Legal in Australia?

Yes — medical cannabis has been legal at the federal level in Australia since February 2016, when the Narcotic Drugs Amendment Act 2016 was passed, enabling the domestic cultivation, production, and manufacture of cannabis for medicinal and scientific purposes. The Therapeutic Goods Administration (TGA) is the primary federal body responsible for regulating access to medicinal cannabis products.

However, "legal" does not mean freely available. All medicinal cannabis products in Australia are prescription medicines. They must be accessed through one of the TGA's regulatory pathways, prescribed by an authorised medical practitioner, and dispensed through a licensed pharmacy.

Medical Cannabis vs Recreational Cannabis: A Key Legal Distinction

The distinction between medical and recreational cannabis is fundamental to understanding Australian law:

• Medical cannabis is a scheduled pharmaceutical product, prescribed by a doctor, regulated by the TGA, and legal under federal and state law when accessed through approved channels.
• Recreational cannabis — the possession, use, supply, or cultivation of cannabis without a valid prescription and outside the medical framework — remains illegal under federal law and under the laws of every Australian state and territory, with the exception of the Australian Capital Territory (ACT).

In the ACT, adults may legally possess up to 50 grams of dried cannabis and grow up to two cannabis plants at home under the Drugs of Dependence (Personal Cannabis Use) Amendment Act 2019. However, supply remains illegal even in the ACT, and federal law has not changed. This creates a legal grey area unique to the ACT and does not apply elsewhere in Australia.

How Medical Cannabis Is Scheduled Under Australian Law

Medicinal cannabis products are listed in the Poisons Standard (the document that schedules therapeutic substances in Australia) primarily under:

• Schedule 4 (Prescription Only Medicine) — applies to most medicinal cannabis products, including those containing cannabidiol (CBD) at prescription concentrations and all products containing THC.
• Schedule 3 (Pharmacist Only Medicine) — applies only to low-dose CBD products (up to 150 mg/day) that have been listed on the Australian Register of Therapeutic Goods (ARTG) as Schedule 3 medicines. As of 2026, very few products meet this threshold and are available over the counter.

The vast majority of medicinal cannabis products that Australian patients use are Schedule 4, requiring a valid prescription.

TGA Regulatory Pathways for Medicinal Cannabis

Because most medicinal cannabis products are not formally "registered" on the ARTG in the way conventional medicines are, doctors must access them through one of several regulatory pathways. As of 2026, the primary routes are:

1. Special Access Scheme – Category B (SAS-B)

This is the most common pathway used by Australian patients. Under SAS-B, any medical practitioner (and in some states, nurse practitioners with relevant endorsements) can apply to the TGA to prescribe an unapproved medicinal cannabis product for an individual patient. Approval is granted on a patient-by-patient, product-by-product basis.

SAS-B applications are assessed by the TGA, which considers the patient's clinical circumstances, the proposed product, and whether the prescribing is appropriate. Since 2021, the TGA has implemented a faster online application process for medicinal cannabis SAS-B applications, and approval rates have been high — the TGA approved over 99% of SAS-B medicinal cannabis applications assessed in the 2022–23 financial year.

2. Authorised Prescriber Scheme

Under this scheme, a medical practitioner can apply to the TGA to become an "Authorised Prescriber" for a specific medicinal cannabis product within a defined patient population (e.g., adults with chronic non-cancer pain). Once approved, an Authorised Prescriber can prescribe that product without submitting an individual SAS-B application for each patient, streamlining the process significantly.

Authorised Prescriber status requires endorsement from a Human Research Ethics Committee (HREC) or a TGA-approved specialist college, and is typically sought by specialist clinics or practitioners with high patient volumes.

3. Clinical Trials

Medicinal cannabis can also be accessed through TGA-approved clinical trials conducted under the Clinical Trial Notification (CTN) or Clinical Trial Approval (CTA) schemes. This pathway is less common for general patient access but contributes to the evidence base for medicinal cannabis in Australia.

4. ARTG-Registered Products

A small but growing number of medicinal cannabis products are now formally registered on the ARTG, meaning they have undergone full TGA evaluation for quality, safety, and efficacy. Registered products can be prescribed by any doctor via a standard prescription, without requiring a SAS-B application. Epidiolex (cannabidiol oral solution), approved for certain childhood epilepsy syndromes, is the most well-known example.

Who Can Prescribe Medical Cannabis in Australia?

Under the SAS-B pathway, any registered medical practitioner in Australia can apply to prescribe medicinal cannabis. This means GPs can initiate and manage medicinal cannabis treatment — specialist referral is not always required, though it is sometimes recommended depending on the condition and complexity.

State and territory regulations may add additional requirements in some circumstances. For example, some states require Schedule 8 permits for products containing THC, since THC is a Schedule 8 (Controlled Drug) substance. Prescribers must comply with both TGA requirements and the relevant state/territory drug and poisons regulations.

Permit requirements can change. Prescribers should verify current requirements with their relevant state or territory health authority before prescribing THC-containing products.

What Conditions Can Medical Cannabis Be Prescribed For?

The TGA does not restrict medicinal cannabis prescribing to a specific list of approved conditions. Under the SAS-B and Authorised Prescriber schemes, prescribers exercise clinical judgement as to whether medicinal cannabis is appropriate for an individual patient, taking into account available evidence, other treatment options, and the patient's circumstances.

In practice, medicinal cannabis is most commonly prescribed in Australia for:

• Chronic non-cancer pain
• Chemotherapy-induced nausea and vomiting
• Anxiety disorders
• Insomnia
• Palliative care symptom management
• Epilepsy (particularly treatment-resistant forms in paediatric patients)
• Multiple sclerosis-related spasticity
• Post-traumatic stress disorder (PTSD)

The clinical evidence supporting medicinal cannabis varies considerably across these conditions. Patients should discuss the current evidence, potential benefits, and risks — including side effects and drug interactions — with their prescribing doctor before commencing treatment. Medicinal cannabis is not appropriate for all patients, and prescribers are best placed to assess individual suitability.

How Patients Can Access Medical Cannabis

The practical steps for a patient seeking legal medicinal cannabis access in Australia are generally as follows:

1. Consult a doctor: Speak with your GP or a specialist about your symptoms and whether medicinal cannabis may be worth exploring. Not all GPs prescribe medicinal cannabis; if yours does not, you can seek a referral or consult a specialist medicinal cannabis clinic.
2. Clinical assessment: Your doctor will assess your medical history, current medications, prior treatments, and suitability for medicinal cannabis. They will consider the available evidence for your condition and discuss realistic expectations with you.
3. TGA approval: If your doctor decides to prescribe, they will submit a SAS-B application to the TGA (or use their Authorised Prescriber status if applicable). The TGA typically processes most medicinal cannabis SAS-B applications within days using the online system.
4. State/territory permit (if required): For THC-containing products, your doctor may need to obtain a state or territory Schedule 8 permit. This runs concurrently with or follows TGA approval.
5. Prescription and dispensing: Once approvals are in place, your doctor issues a prescription. Medicinal cannabis products are dispensed by pharmacies — many are available through compounding pharmacies or specialist dispensing services, and some can be delivered by mail order where permitted.
6. Ongoing management: Your prescribing doctor should review your response to treatment, monitor for side effects, and adjust treatment as needed. Medicinal cannabis is a prescription medicine, and ongoing medical oversight is important.

Cost and PBS Listing

As of 2026, medicinal cannabis products are not listed on the Pharmaceutical Benefits Scheme (PBS), with the exception of nabiximols (Sativex) for MS-related spasticity under specific criteria. This means that for most patients, medicinal cannabis is an out-of-pocket expense. Costs vary significantly depending on the product, dose, and formulation, but can range from approximately $100 to $400 or more per month. Patients should discuss costs with their prescriber and pharmacy before commencing treatment.

Driving and Medicinal Cannabis

This is a critical legal issue for Australian patients. Roadside drug testing in Australia detects the presence of THC — not impairment — using oral fluid tests. In most Australian states and territories, driving with any detectable level of THC in your system is an offence, regardless of whether you hold a valid prescription. Medicinal cannabis authorisation does not currently provide a legal defence to a positive roadside drug test in most jurisdictions.

Patients prescribed THC-containing medicinal cannabis must exercise extreme caution regarding driving. Speak to your prescriber about the implications for your specific situation and refer to your state or territory's road rules authority for current guidance.

Sources

• TGA Medicinal Cannabis Hub — Therapeutic Goods Administration
• TGA: Access to Medicinal Cannabis Products — FAQs
• Narcotic Drugs Amendment Act 2016 — Federal Register of Legislation
• TGA Special Access Scheme Guidance
• Australian Government Department of Health — Medicinal Cannabis
• Drugs of Dependence (Personal Cannabis Use) Amendment Act 2019 — ACT Legislation Register
• TGA Medicinal Cannabis Annual Report 2022–23